IRVINE, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences.
Citi BioPharma Conference
Date: Wednesday, September 6 – Thursday, September 7, 2023
Location: Four Seasons, Boston, MA
Baird Global Healthcare Conference
Date: Tuesday, September 12 – Wednesday, September 13, 2023
Location: InterContinental New York Barclay, New York, NY
Leerink Partners Biopharma Summit
Date: Wednesday, September 20 – Friday, September 22, 2023
Location: Rosewood Miramar Beach, Montecito, CA
Cantor Global Healthcare Conference
Date: Tuesday, September 26 – Thursday, September 28, 2023
Location: InterContinental New York Barclay, New York, NY
Links to the presentations will be posted on the Investors section of the Reneo Pharmaceuticals corporate website.
About Reneo Pharmaceuticals
Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar (REN001), is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function, increase fatty acid oxidation, and may increase production of new mitochondria. For additional information, please see reneopharma.com.
Contacts:
Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Matthew Purcell, Pharm.D.
Media Inquiries
Russo Partners, LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.82 |
| Daily Volume: | 0 |
| Market Cap: | US$60.840M |
October 04, 2024 March 28, 2024 | |
Else Nutrition is changing the face of early childhood nutrition with clean, sustainable, plant-based products. The company has developed the world’s first whole plant-based infant formula that is targeting the $100+ billion global...
CLICK TO LEARN MORE
DevvStream provides upfront capital for sustainability projects in exchange for carbon credit rights. Through these rights, the company generates and manages carbon credits by utilizing the most technologically advanced...
CLICK TO LEARN MORE